Lilly reports retatrutide weight loss in pivotal phase 3 obesity trial
The triple agonist is the company's next candidate behind tirzepatide, and the readout sets up a regulatory filing decision.
MH
By Maren Holt · Senior Reporter, GLP-1
May 21 03:00 ETSource: Eli Lilly
The wire
- 01Eli Lilly said its GIP/GLP-1/glucagon triple agonist retatrutide delivered substantial weight loss in a pivotal phase 3 obesity trial.
- 02A positive pivotal readout moves retatrutide toward filing and reshapes the competitive picture for prescribers and payers planning incretin formularies.
- 03The announcement is a company release; full endpoint, tolerability and discontinuation data await peer-reviewed presentation.
From the source
Read at investor.lilly.comLilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
